Pharmacological inhibition of soluble epoxide hydrolase prevents renal interstitial fibrogenesis in obstructive nephropathy.

@article{Kim2015PharmacologicalIO,
  title={Pharmacological inhibition of soluble epoxide hydrolase prevents renal interstitial fibrogenesis in obstructive nephropathy.},
  author={Jinu Kim and Sang-Pil Yoon and Myron Lee Toews and John D Imig and Sung Hee Hwang and Bruce D Hammock and Babu J Padanilam},
  journal={American journal of physiology. Renal physiology},
  year={2015},
  volume={308 2},
  pages={
          F131-9
        }
}
Treating chronic kidney disease (CKD) has been challenging because of its pathogenic complexity. Epoxyeicosatrienoic acids (EETs) are cytochrome P-450-dependent derivatives of arachidonic acid with antihypertensive, anti-inflammatory, and profibrinolytic functions. We recently reported that genetic ablation of soluble epoxide hydrolase (sEH), an enzyme that converts EETs to less active dihydroxyeicosatrienoic acids, prevents renal tubulointerstitial fibrosis and inflammation in experimental… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 27 CITATIONS

Inhibition of Soluble Epoxide Hydrolase for Renal Health

  • Front. Pharmacol.
  • 2018
VIEW 4 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Prenyl-flavonoids from Epimedium koreanum Nakai and their soluble epoxide hydrolase and tyrosinase inhibitory activities

Xiang Dong Su, Wei Li, +3 authors Young Ho Kim
  • Medicinal Chemistry Research
  • 2017
VIEW 1 EXCERPT
HIGHLY INFLUENCED

References

Publications referenced by this paper.
SHOWING 1-10 OF 65 REFERENCES